Novartis May Sell Dermatology Generics Unit

Nov 01, 2017

Novartis is considering a sale of its dermatology generics drugs business as the company looks to focus on growth areas, says Bloomberg sources.

The Sandoz dermatology business assets for sale include skin-care treatments and some manufacturing facilities, mostly U.S.- based. Sources say the sale could be valued at between $1 billion to $1.5 billion.

Sandoz bought U.S.-based Fougera Pharmaceuticals for $1.5 billion in 2012, becoming the top seller of generic skin medications. Last year, it acquired the AmLactin skin-care brands from U.S.-based Upsher-Smith Labs.

Earlier this week, Novartis announced that it will buy Advanced Accelerator Applications -- a radiopharmaceutical company whose drugs are used to diagnose and treat diseases such as cancer -- for about $3.9 billion in cash.

Read the Bloomberg coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments